[Item 1: Reporting Person: Wasatch Advisors, Inc. 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 1,227,075 Item 6: Shared Voting Power: 0 Item 7: Sole Dispositive Power: 1,227,075 Item 8: Shared Dispositive Power: 0 Item]
[21Vianet Group, Inc. Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results 4Q13 Net Revenues Up 30.6% YOY to RMB545.9 Million 4Q13 Adjusted EBITDA Up 31.4% YOY to RMB102.9 Million Live Conference Call to be Held at 8:00 PM U.S. Eastern Time, March 6, 2014 BEIJING, March 6, 2014 (GLOBE NEWSWIRE) 21Vianet Group, Inc. (Nasdaq: VNET) (21Vianet or] [EXPLANATORY NOTE 21Vianet Group, Inc. By : Shang-Wen Hsiao Chief Financial Officer Press Release 6-K/A 1 d688339d6ka.htm AMENDMENT NO. 1 TO FORM 6-K]
[Prospectus Supplement To Prospectus Dated December 31, 2013 Registration No. 333-192963 Biostar Pharmaceuticals, Inc. 1,650,000 shares of common stock Our shares of common stock are currently traded on the Nasdaq Capital Market under the symbol “BSPM.” On March 7, 2014, the closing sale price of our shares of common stock was $2.97 per share. Risk Factors Investing in our securities]
[21Vianet Group, Inc. Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results 4Q13 Net Revenues Up 30.6% YOY to RMB545.9 Million 4Q13 Adjusted EBITDA Up 31.4% YOY to RMB102.9 Million Live Conference Call to be Held at 8:00 PM U.S. Eastern Time, March 6, 2014 BEIJING, March 6, 2014 (GLOBE NEWSWIRE) 21Vianet Group, Inc. (Nasdaq: VNET) (21Vianet or] [EXPLANATORY NOTE 21Vianet Group, Inc. By : Shang-Wen Hsiao Chief Financial Officer Press Release 6-K/A 1 d688339d6ka.htm AMENDMENT NO. 1 TO FORM 6-K]
[Prospectus Supplement To Prospectus Dated December 31, 2013 Registration No. 333-192963 Biostar Pharmaceuticals, Inc. 1,650,000 shares of common stock Our shares of common stock are currently traded on the Nasdaq Capital Market under the symbol “BSPM.” On March 7, 2014, the closing sale price of our shares of common stock was $2.97 per share. Risk Factors Investing in our securities]
[Fuwei Films Announces Receipt of the Fifth Notice of Proposed Public Auction of Controlling Interest BEIJING, March 7, 2014 /PRNewswire/ -- Fuwei Films (Holdings) Co., Ltd. (NASDAQ: FFHL, "Fuwei Films" or the "Company"), announced today that it has received a fifth notice from its controlling shareholder, the Weifang State-owned Assets Operation Administration Company, a wholly-owned subsidiary of Weifang State-owned Asset] []
[CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC. 208 Summitrail Lane Dawsonville, GA 30524 Phone (770) 815-0885 Mr. Ronghua Wang Chairman and CEO Biostar Pharmaceuticals, Inc No. 588 Shiji Xi Avenue Xianyang, 712046 Phone: 86 29 3368 6638 Dear Mr. Wang: “ Moody Capital Solutions, Inc. Axiom Capital Management, Inc Biostar Pharmaceuticals, Inc. This letter (the The terms of such] [BIOSTAR PHARMACEUTICALS, INC. Issuance Date Date of Issuance: March [___], 2014 (“ Company Holder 1 16 Securities Purchase Agreement Biostar Pharmaceuticals, Inc., a Maryland corporation (the “ 1. (a) Mechanics of Exercise 1 (f) Exercise Notice Aggregate Exercise Price 1 (d) st . Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1] [March 10, 2014 Board of Directors Biostar Pharmaceuticals, Inc. No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People’s Republic of China 712046 Company Shares Shares Shares Securities Purchase Agreement Registration Statement Commission Act Base Prospectus Prospectus Supplement Prospectus Schiff Hardin LLP EX-5.1 4 ex5-1.htm EX-5.1] [SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT Agreement Company Buyer Buyers This RECITALS Registration Statement 1933 Act SEC Common Shares Common Stock B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms stated in this Agreement, (i) the aggregate number of shares of Common Stock (as defined below) set forth opposite such Buyer’s name in column] [Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, are expected to be approximately $4.1 million. The net proceeds from this offering will be used for working capital and other general corporate purposes. The completion of the offering will occur on or before March 13, 2014. Moody Capital Solutions, Inc.] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): March 10, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
[Fuwei Films Announces Receipt of the Fifth Notice of Proposed Public Auction of Controlling Interest BEIJING, March 7, 2014 /PRNewswire/ -- Fuwei Films (Holdings) Co., Ltd. (NASDAQ: FFHL, "Fuwei Films" or the "Company"), announced today that it has received a fifth notice from its controlling shareholder, the Weifang State-owned Assets Operation Administration Company, a wholly-owned subsidiary of Weifang State-owned Asset] []
[CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC. 208 Summitrail Lane Dawsonville, GA 30524 Phone (770) 815-0885 Mr. Ronghua Wang Chairman and CEO Biostar Pharmaceuticals, Inc No. 588 Shiji Xi Avenue Xianyang, 712046 Phone: 86 29 3368 6638 Dear Mr. Wang: “ Moody Capital Solutions, Inc. Axiom Capital Management, Inc Biostar Pharmaceuticals, Inc. This letter (the The terms of such] [BIOSTAR PHARMACEUTICALS, INC. Issuance Date Date of Issuance: March [___], 2014 (“ Company Holder 1 16 Securities Purchase Agreement Biostar Pharmaceuticals, Inc., a Maryland corporation (the “ 1. (a) Mechanics of Exercise 1 (f) Exercise Notice Aggregate Exercise Price 1 (d) st . Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1] [March 10, 2014 Board of Directors Biostar Pharmaceuticals, Inc. No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People’s Republic of China 712046 Company Shares Shares Shares Securities Purchase Agreement Registration Statement Commission Act Base Prospectus Prospectus Supplement Prospectus Schiff Hardin LLP EX-5.1 4 ex5-1.htm EX-5.1] [SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT Agreement Company Buyer Buyers This RECITALS Registration Statement 1933 Act SEC Common Shares Common Stock B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms stated in this Agreement, (i) the aggregate number of shares of Common Stock (as defined below) set forth opposite such Buyer’s name in column] [Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, are expected to be approximately $4.1 million. The net proceeds from this offering will be used for working capital and other general corporate purposes. The completion of the offering will occur on or before March 13, 2014. Moody Capital Solutions, Inc.] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): March 10, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
[(Name of Issuer) Ordinary Shares (Title of Class of Securities) (CUSIP Number) February 28, 2014 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY 4. CITIZENSHIP]
